BioVie (BIVI) vs Intensity Therapeutics (INTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioVie (BIVI) has outperformed Intensity Therapeutics (INTS) over the past year, losing 35.0% versus a loss of 48.4%. Intensity Therapeutics is the larger company by market cap ($12.0 million vs $11.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | INTS |
|---|---|---|
| Share price | $1.28 | $3.68 |
| Market cap | $11.11M | $12.01M |
| 1-day change | -8.57% | -3.16% |
| YTD return | +10.34% | -64.10% |
| 1-year return | -35.03% | -48.35% |
| 5-year return | -99.78% | — |
| EPS (TTM) | $-3.05 | $-3.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.79 | $43.50 |
| 52-week low | $0.82 | $3.21 |
| Distance from 52-week high | -66.23% | -91.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +310.94% | +425.27% |
| Average volume | 4.60M | 25.93K |
| Shares outstanding | 8.68M | 3.26M |
| Employees | 13 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIVI has outperformed INTS by 13.3 percentage points over the past year.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Intensity Therapeutics
INTS stock →Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
BIVI vs INTS FAQ
Which is bigger, BioVie or Intensity Therapeutics?
Intensity Therapeutics (INTS) is larger, with a market capitalization of $12.01M compared with $11.11M for BioVie (BIVI).
Which stock has performed better over the past year, BIVI or INTS?
BIVI returned -35.03% over the past 12 months, compared with -48.35% for INTS (price return, excluding dividends). Past performance does not predict future results.
Are BioVie and Intensity Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for BioVie and Biotechnology: Biological Products (No Diagnostic Substances) for Intensity Therapeutics.